Last reviewed · How we verify

RRx-001 + eLOOP Device — Competitive Intelligence Brief

RRx-001 + eLOOP Device (RRx-001 + eLOOP Device) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunotherapeutic small molecule. Area: Oncology.

phase 3 Immunotherapeutic small molecule Oncology Small molecule Live · refreshed every 30 min

Target snapshot

RRx-001 + eLOOP Device (RRx-001 + eLOOP Device) — EpicentRx, Inc.. RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
RRx-001 + eLOOP Device TARGET RRx-001 + eLOOP Device EpicentRx, Inc. phase 3 Immunotherapeutic small molecule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunotherapeutic small molecule class)

  1. EpicentRx, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RRx-001 + eLOOP Device — Competitive Intelligence Brief. https://druglandscape.com/ci/rrx-001-eloop-device. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: